No abstract

Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed human epidermal growth factor 2–positive early breast cancer were randomly assigned to 1 year of adjuvant therapy with T, L, their sequence (T→L), or their combination (L+T). The primary end point was disease-free survival (DFS), with 850 events required for 80% power to detect a hazard ratio (HR) of 0.8 for L+T versus T. Results Between June 2007 and July 2011, 8,381 patients were enrolled. In 2011, due to futility to demonstrate noninferiority of L versus T, the L arm was closed, and patients free of disease were offered adjuvant T. A protocol modification required P ≤ .025 for the two remaining pairwise comparisons. At a protocol-specified analysis with a median follow-up of 4.5 years, a 16% reduction in the DFS hazard rate was observed with L+T compared with T (555 DFS events; HR, 0.84; 97.5% CI, 0.70 to 1.02; P = .048), and a 4% reduction was observed with T→L compared with T (HR, 0.96; 97.5% CI, 0.80 to 1.15; P = .61). L-treated patients experienced more diarrhea, cutaneous rash, and hepatic toxicity compared with T-treated patients. The incidence of cardiac toxicity was low in all treatment arms. Conclusion Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity. One year of adjuvant T remains standard of care.

LBA4 Background: Lapatinib (L) is a HER1-HER2 tyrosine kinase inhibitor. The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) Trial is a randomised, phase III trial comparing 3 oral L-containing regimens with T, each given for 1 year. Methods: From June 2007 to July 2011, 8381 patients (pts) were randomised from 946 sites in 44 countries to receive either L+T, T→L, L, or T. Anti-HER2 therapy was initiated after completing all chemotherapy (N=4613), concurrently with a taxane following anthracycline (N=3337), or concurrently with a non-anthracycline, platinum-containing regimen (N=431). The L arm was closed in Aug 2011 for futility and is not presented. The primary endpoint is invasive disease-free survival (DFS). L+T vs. T is tested for superiority and T→L vs. T is tested for non-inferiority at 1.11 margin. P≤0.025 is required for statistical significance. 850 DFS events in the L+T vs. T comparison would provide 80% power to detect a true hazard ratio (HR) of 0.80 with experiment-wide alpha=0.05. The current analysis was planned to occur either after observing these 850 events or at 4.5 yrs median follow up (MFU). Results: Pt and disease characteristics were well balanced. 40% were node-negative and 57% were hormone receptor positive. Only 555 DFS events for the L+T vs. T comparison were observed at 4.5 years MFU. HR for DFS was 0.84 (97.5% CI, 0.70-1.02; P=0.048; 4-yr DFS%=88% vs. 86%) for L+T vs. T and 0.93 (97.5% CI, 0.76-1.13; non-inferiority P=0.044; 4-yr DFS%=87% vs. 86%) for T→L vs. T. Diarrhoea (75% vs. 20%), rash (55% vs. 20%) and hepatobiliary (23% vs. 16%) adverse events were more frequent in L+T vs. T. Primary cardiac endpoints were infrequent (<1%) in all arms. Conclusions: L+T has lower risk of a DFS event compared with T, and T→L appeared non-inferior to T, but neither finding was statistically significant. The first DFS results of dual HER2 blockade in the adjuvant ALTTO at 4.5 years MFU are unexpected considering the effect shown by doubling the pCR rate with L+T vs. T in the NeoALLTO trial. Follow up continues. Clinical trial information: NCT00490139.

The paradigm shift to more distributed flood risk management strategies in the UK involves devolved responsibilities to the local, and the need to enhance risk ownership by communities. This poses questions about how communities build resilience to future flood risk, and how agencies support these processes. This paper explores results from interdisciplinary research on 'sustainable flood memory' in the context of effective flood risk management as a conceptual contribution to a global priority. The project aimed to increase understanding of how flood memories provide a platform for developing and sharing lay knowledges, creating social learning opportunities to increase communities' adaptive capacities for resilience. The paper starts by conceptually framing resilience, community, lay knowledge and flood memory. It then explores key themes drawn from semi-structured interviews with floodplain residents affected by the UK summer 2007 floods in four different settings, which contrasted in terms of their flood histories, experiences and kinds of 'communities'. Sustainable flood memories were found to be associated with relational ways of knowing, situated in emotions, changing materiality and community tensions. These all influenced active remembering and active forgetting. The paper reflects on varying integrations of memory, lay knowledges and resilience, and critically evaluates implications of the sustainable flood memory concept for the strategy, process and practice of developing community flood resilience. Given the concept's value and importance of 'memory work', the paper proposes a framework to translate the concept practically into community resilience initiatives, and to inform how risk and flood experiences are communicated within communities.

Abstract. 6KLIWV WR GHYROYHG IORRG ULVN PDQDJHPHQW LQ WKH 8. SRVH TXHVWLRQV DERXW KRZ WKH FKDQJLQJ UROH RI IORRGSODLQ UHVLGHQWV LQ FRPPXQLW\OHG DGDSWDWLRQ SODQQLQJ FDQ EH VXSSRUWHG DQG VWUHQJWKHQHG 7KLV SDSHU VKDUHV LQVLJKWV IURP DQ LQWHUGLVFLSOLQDU\ UHVHDUFK SURMHFW WKDW KDV SURSRVHG WKH FRQFHSW RI µVXVWDLQDEOH IORRG PHPRU\ ¶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